MethylGene Updates On Multi-Targeted Kinase Inhibitor Program, Discloses Additional Anti-Angiogenic Targets

MethylGene Inc. (TSX:MYG) a biopharmaceutical company, today announced preclinical results regarding its multi-targeted kinase inhibitor program in a poster entitled, “Novel, Orally Active Multi-Kinase Inhibitors of c-Met and VEGF Receptor Family Exhibit Potent Antiangiogenic Activity and Antitumour Efficacy in Preclinical Models” (Poster A262). These date were presented during the EORTC-NCI-AACR (European Organisation for Research and Treatment of Cancer, National Cancer Institute, American Association for Cancer Research) International Conference on Molecular Targets and Cancer Therapeutics, which met in Philadelphia from November 14-17, 2005. The data also disclosed that in addition to c-met and all three VEGF receptor targets, MethylGene’s lead molecules also target Tie-2, and Ron kinases.